CENTOGENE Regains Compliance With Nasdaq Listing Requirements

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received notifications from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) and with the minimum Market Value of Publicly Held Shares (“MVPHS”) requirement for continued listing on the Nasdaq under Nasdaq Listing Rules 5450(b)(3)(C).

As a result, CENTOGENE is now compliant with all applicable Nasdaq listing standards, and Nasdaq considers these matters closed.

CENTOGENE was previously notified by Nasdaq on April 24, 2023, that the Company was not in compliance with the minimum bid price rule, because its common stock failed to meet the closing bid price of USD 1.00 or more for 30 consecutive business days. To regain compliance with the minimum bid price rule, the Company was required to maintain a minimum closing bid price of USD 1.00 for at least 10 consecutive business days. This requirement was met on July 12, 2023.

CENTOGENE was previously notified by Nasdaq on June 8, 2023, that the Company was not in compliance with the minimum MVPHS set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. To regain compliance, the Company was required to maintain a MVPHS at USD 15 million or more for a minimum of 10 consecutive business days. This requirement was met on July 13, 2023.

About CENTOGENE

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.